The global HPV vaccine market, valued at $9.73 billion in 2025, is projected to reach $29.63 billion by 2035, growing at a CAGR of 11.78%. Rising cervical cancer awareness, government vaccination programs, improved vaccine technology, and AI-driven distribution are driving growth. North America leads, while Asia-Pacific is the fastest-growing region, reflecting shift toward preventive healthcare.